home / stock / adxsd / adxsd news
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level MONMOUTH JUNCTION, N.J., June 29, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnol...
News, Short Squeeze, Breakout and More Instantly...
Advaxis Inc. Company Name:
ADXSD Stock Symbol:
OTCMKTS Market:
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level MONMOUTH JUNCTION, N.J., June 29, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnol...